Video

Dr. George Somlo on Advances in Multiple Myeloma

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Several new agents have been approved by the FDA in the past year, and oncologists are quickly learning how to best use them, says Somlo.

More and more patients are experiencing complete remissions, or at the least, very good partial remissions that eliminate 90% of the mutational load. Many of those patients can then receive an autologous stem cell transplant and the receive maintenance therapy, accomplishing minimal residual disease.

This directly translates into longer survival and a dramatically improved quality of life, says Somlo.

Oncologists that treat patients with multiple myeloma need to be aggressive, use the latest tools and agents, and enroll patients in clinical trials when applicable, says Somlo.

Related Videos
Michel Delforge, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.